PDCD1 and non-small cell lung carcinoma: Researchers also found that in non-small cell lung cancer, EGFR-mutant and ALK-rearranged tumors responded poorly to anti-PD-1/PD-L1 treatment and exhibited higher infiltrations of CD4+ memory resting T cells [37].